MX385276B - Tratamiento para la enfermedad de parkinson - Google Patents

Tratamiento para la enfermedad de parkinson

Info

Publication number
MX385276B
MX385276B MX2018014944A MX2018014944A MX385276B MX 385276 B MX385276 B MX 385276B MX 2018014944 A MX2018014944 A MX 2018014944A MX 2018014944 A MX2018014944 A MX 2018014944A MX 385276 B MX385276 B MX 385276B
Authority
MX
Mexico
Prior art keywords
alkyl
haloalkyl
hydrogen
disease
parkinson
Prior art date
Application number
MX2018014944A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014944A (es
Inventor
Gajanan Uttamrao Chidrewar
Manoj Atmaramji Upadhya
Nitin Krishnaji Damle
Prabal Sengupta
Sameer Vishwanath Mehetre
Sanjay Nandlalji Mandhane
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2018014944A publication Critical patent/MX2018014944A/es
Publication of MX385276B publication Critical patent/MX385276B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018014944A 2016-06-02 2017-06-02 Tratamiento para la enfermedad de parkinson MX385276B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (2)

Publication Number Publication Date
MX2018014944A MX2018014944A (es) 2019-03-07
MX385276B true MX385276B (es) 2025-03-18

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014944A MX385276B (es) 2016-06-02 2017-06-02 Tratamiento para la enfermedad de parkinson

Country Status (26)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
EP3982964A1 (en) * 2019-06-11 2022-04-20 Sun Pharma Advanced Research Company Ltd Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
CA3251516A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Methods of reducing progression of neurodegenerative disease
KR20250040552A (ko) 2023-09-14 2025-03-24 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665709B1 (en) * 2011-01-21 2016-12-07 Sun Pharma Advanced Research Company Limited Diarylacetylene hydrazide containing tyrosine kinase inhibitors
DK2844256T3 (da) 2012-05-02 2023-03-27 Univ Georgetown Behandling af amyotrofisk lateral sklerose med tyrosinkinase-inhibitorer
CA2985161A1 (en) * 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
LT3463351T (lt) * 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas

Also Published As

Publication number Publication date
PH12018502457B1 (en) 2022-01-12
US20190275017A1 (en) 2019-09-12
KR102508288B1 (ko) 2023-03-09
MY193754A (en) 2022-10-27
US20210015805A1 (en) 2021-01-21
LT3463351T (lt) 2022-06-10
EP3463351B1 (en) 2022-04-27
US20220273632A1 (en) 2022-09-01
SG11201810294QA (en) 2018-12-28
CL2018003431A1 (es) 2019-05-10
UA123018C2 (uk) 2021-02-03
US11813252B2 (en) 2023-11-14
PL3463351T3 (pl) 2022-06-20
DK3463351T3 (da) 2022-06-07
HRP20220683T1 (hr) 2022-07-08
IL263188B (en) 2021-08-31
RS63243B1 (sr) 2022-06-30
CA3024976A1 (en) 2017-12-07
CN109475539A (zh) 2019-03-15
SMT202200228T1 (it) 2022-07-21
US20240066014A1 (en) 2024-02-29
IL263188A (en) 2018-12-31
MX2018014944A (es) 2019-03-07
CN109475539B (zh) 2021-12-28
KR20190015257A (ko) 2019-02-13
US10849887B2 (en) 2020-12-01
AU2017273415A1 (en) 2018-12-06
CY1125285T1 (el) 2025-03-28
BR112018074439A2 (pt) 2019-03-06
PH12018502457A1 (en) 2019-10-21
JP6974357B2 (ja) 2021-12-01
HUE059387T2 (hu) 2022-11-28
US11583522B2 (en) 2023-02-21
ES2914782T3 (es) 2022-06-16
SI3463351T1 (sl) 2022-07-29
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
NZ748592A (en) 2025-11-28
EP3463351A1 (en) 2019-04-10
PT3463351T (pt) 2022-06-02
WO2017208267A1 (en) 2017-12-07
EP4085912A1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
MX2018014944A (es) Tratamiento para la enfermedad de parkinson.
MX2020000261A (es) Nuevos compuestos.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CR20180022A (es) Derivados etinilo.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR091285A1 (es) Inhibidores de bromodominio y sus usos
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
PE20140934A1 (es) Derivados de pirazol
UY36257A (es) “compuestos de imidazopiridazina”.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR081821A1 (es) Antranilamidas sustituidas con triazol como plaguicidas
UY31824A (es) Nuevos compuestos
CU20100252A7 (es) Derivados de dibenzotiazepina
MX390507B (es) Compuestos de amida y su uso.
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
MX345264B (es) Derivado de azol.
AR116051A1 (es) Derivados de heteroarilo bicíclicos